Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arca Biopharma (ABIO)
NASDAQ:ABIO
Holding ABIO?
Track your performance easily
ABIO Stock Chart & Stats
Day’s Range$26.64 - $29.64
52-Week Range― - ―
Previous Close$30
Volume290.85K
Average Volume (3M)N/A
Market Cap
$33.84M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Feb 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 29, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Arca Biopharma News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABIO FAQ
What was Arca Biopharma’s price range in the past 12 months?
Currently, no data Available
What is Arca Biopharma’s market cap?
Currently, no data Available
When is Arca Biopharma’s upcoming earnings report date?
Arca Biopharma’s upcoming earnings report date is Feb 20, 2025 which is in 112 days.
How were Arca Biopharma’s earnings last quarter?
Arca Biopharma released its earnings results on Aug 01, 2024. The company reported -$2.215 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.215.
Is Arca Biopharma overvalued?
According to Wall Street analysts Arca Biopharma’s price is currently Overvalued.
Does Arca Biopharma pay dividends?
Arca Biopharma pays a Notavailable dividend of $19.08 which represents an annual dividend yield of N/A. See more information on Arca Biopharma dividends here
What is Arca Biopharma’s EPS estimate?
Arca Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arca Biopharma have?
Currently, no data Available
What happened to Arca Biopharma’s price movement after its last earnings report?
Arca Biopharma reported an EPS of -$2.215 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.079%.
Which hedge fund is a major shareholder of Arca Biopharma?
Among the largest hedge funds holding Arca Biopharma’s share is Perceptive Advisors LLC. It holds Arca Biopharma’s shares valued at 59M.
---
Arca Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ABIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 9.2%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.65%
12-Months-Change
Fundamentals
Return on Equity
-20.05%
Trailing 12-Months
Asset Growth
-17.62%
Trailing 12-Months
Company Description
Arca Biopharma
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
---
Technical Analysis
Best Analysts Covering ABIO
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
initiated a buy rating 2 months ago
Copying David Nierengarten's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---